Cellectis, a clinical-stage biotechnology company, was asked by the FDA to place a clinical hold on 2 phase 1 trials evaluating its allogeneic chimeric antigen receptor-T (CAR-T) cell treatments following the report of a fatality in the first patient treated in one of the studies.
Cellectis, a clinical-stage biotechnology company, was asked by the FDA to place a clinical hold on 2 phase 1 trials evaluating its allogeneic chimeric antigen receptor-T (CAR-T) cell treatments following the report of a fatality in the first patient treated in one of the studies.
The company has initiated 2 phase 1 studies using gene-edited allogeneic CAR-T cells (UCART123), which are being tested in acute myeloid leukemia (AML) and in blastic plasmacytoid dendritic cell neoplasm (BPDCN). The first patient treated in the BPDCN trial, who had received 1 prior line of treatment, was administered a preconditioning regimen of 30 mg/m2 fludarabine daily for 4 days and 1 g/m2 cyclophosphamide daily for 3 days.
Soon after (5 days) the first infusion of the modified UCART123 cells was administered, the patient experienced grade 2 cytokine release syndrome (CRS) and a grade 3 lung infection, which were treated with tociluzumab and broad-spectrum antibiotics. Three days after, the patient came down with grade 5 CRS and grade 4 capillary leak syndrome (CLS). Immediate standard-of-care treatment proved insufficient and the patient died the next day.
A patient in the AML study who was treated with the same preconditioning regimen and was administered the same dose of UCART123 experienced similar adverse events: an initial grade 2 CRS that worsened to grade 3, but resolved following management in the intensive care unit—as did her grade 4 CLS.
In the summer of 2016, Juno Therapeutics was directed by the FDA to dissolve the phase 2 evaluation of JCAR015 in patients with relapsed/refractory B cell acute lymphoblastic leukemia (ALL) following 3 patient deaths due to cerebral edema. The company initially proposed changing its preconditioning regimen and eliminating fludarabine from the protocol. However, in early 2017, the company announced that it had terminated the trial following additional deaths.
For Cellectis, its Data Safety Monitoring Board has proposed lowering the dose of cell infusion as well as restricting the dose of the chemotherapy, cyclophosphamide, that the patients receive as preconditioning treatment.
Although Novartis received unanimous support from the FDA’s Oncologic Drugs Advisory Committee, and subsequent FDA approval, for tisagenlecleucel (Kymriah) in pediatric and young adult patients with B-cell ALL, the Cellectis and Juno experiences point to the need for caution with this treatment modality.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More